

Rebecca Leyland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2543089/publications.pdf>

Version: 2024-02-01

17
papers

1,186
citations

840776

11
h-index

1199594

12
g-index

17
all docs

17
docs citations

17
times ranked

2547
citing authors

#	ARTICLE	IF	CITATIONS
1	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. <i>Cancer Immunology Research</i> , 2017, 5, 29-41.	3.4	321
2	miR-155: an ancient regulator of the immune system. <i>Immunological Reviews</i> , 2013, 253, 146-157.	6.0	286
3	MicroRNA-155 Is Required for <i>Mycobacterium bovis</i> BCG-Mediated Apoptosis of Macrophages. <i>Molecular and Cellular Biology</i> , 2012, 32, 2239-2253.	2.3	126
4	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 568931.	4.8	100
5	Characterisation of 5-HT _{3C} , 5-HT _{3D} and 5-HT _{3E} receptor subunits: evolution, distribution and function. <i>Journal of Neurochemistry</i> , 2009, 108, 384-396.	3.9	88
6	The miR-155/Pu.1 axis acts on Pax5 to enable efficient terminal B cell differentiation. <i>Journal of Experimental Medicine</i> , 2014, 211, 2183-2198.	8.5	83
7	Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 68278-68291.	1.8	48
8	A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist. <i>Clinical Cancer Research</i> , 2017, 23, 3416-3427.	7.0	42
9	MicroRNA-155 controls affinity-based selection by protecting c-MYC+ B cells from apoptosis. <i>Journal of Clinical Investigation</i> , 2015, 126, 377-388.	8.2	41
10	Epigenomic Modifications Mediating Antibody Maturation. <i>Frontiers in Immunology</i> , 2018, 9, 355.	4.8	28
11	MicroRNA-155 is essential for the optimal proliferation and survival of plasmablast B cells. <i>Life Science Alliance</i> , 2019, 2, e201800244.	2.8	17
12	Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1723-1734.	4.1	5
13	Abstract 561: MEDI1873: A novel hexameric GITRL fusion protein with potent agonistic and immunomodulatory activities in preclinical systems. , 2016, , .		1
14	A mouse GITRL fusion protein drives T cell activation and antitumor activity in preclinical mouse models of cancer. , 2015, 3, .		0
15	Abstract 4902: A mouse GITRL fusion protein drives T-cell activation and antitumor activity in preclinical mouse models of cancer. , 2016, , .		0
16	Abstract 4186: Syngenic fingerprint: the biomic characterization of the mouse syngeneic tumor models. , 2016, , .		0
17	Abstract 4604: MEDI1873, a GITR ligand fusion protein (GITRL FP), induces effector T-cell proliferation, modulates T-regulatory cell function and has the potential to combine with checkpoint inhibitors. , 2017, , .		0